Citations

Showing 10 of 108083 citations.

Diagnostic Performance of ACR and Kwak TI-RADS for Benign and Malignant Thyroid Nodules: An Update Systematic Review and Meta-Analysis
Kang, Yun Jin , Stybayeya, Gulnaz , Lee, Ju Eun , Hwang, Se Hwan , Stybayeva, Gulnaz , Hwang, Se Hwan , Lee, Ju Eun

Mayo Clinic

Cancers | December 2, 2022 | Volume: 14 | Issue: 23 | Pages: 5961

10.3390/cancers14235961 | PMID 36497443 Get It

(1) Background: To determine the optimal cut-off values of two risk stratification systems to discriminate malignant thyroid nodules and to compare the diagnostic performance; (2) Methods: True and false positive and negative data were collected, and methodological quality was assessed for forty-six studies involving 39,085 patients; (3) Results: The highest area under the receiver operating characteristic (ROC) curve (AUC) of ACR and Kwak TI-RADS were 0.875 and 0.884. Based on the optimal sensitivity and specificity, the highest accuracy values of ROC curves or diagnostic odds ratios (DOR) were taken as the cut-off values for TR4 (moderate suspicious) and 4B. The sensitivity, specificity, DOR, and AUC by ACR (TR4) and Kwak TI-RADS (4B) for malignancy risk stratification of thyroid nodules were 94.3% and 96.4%; 52.2% and 53.7%; 17.5185 and 31.8051; 0.786 and 0.884, respectively. There were no significant differences in diagnostic accuracy in any of the direction comparisons of the two systems; (4) Conclusions: ACR and Kwak TI-RADS had good diagnostic performances (AUCs > 85%). Although we determined the best cut-off values in individual risk stratification systems based on statistical assessment, clinicians can adjust the optimal cut-off value according to the clinical purpose of the ultrasonography because raising or lowering cut-points leads to reciprocal changes in sensitivity and specificity.
Characteristics of Kidney Recipients of High Kidney Donor Profile Index Kidneys as Identified by Machine Learning Consensus Clustering
Radhakrishnan, Yeshwanter , Jadlowiec, Caroline C. , Mao, Michael A. , Vaitla, Pradeep , Acharya, Prakrati , Leeaphorn, Napat , Kaewput, Wisit , Pattharanitima, Pattharawin , Tangpanithandee, Supawit , Krisanapan, Pajaree , Nissaisorakarn, Pitchaphon , Cooper, Matthew , Cheungpasitporn, Wisit , Radhakrishnan, Yeshwanter , Jadlowiec, Caroline , Mao, Michael A , Kaewput, Wisit , Pattharanitima, Pattharawin , Tangpanithandee, Supawit , Krisanapan, Pajaree , Nissaisorakarn, Pitchaphon , Cooper, Matthew , Cheungpasitporn, Wisit , Thongprayoon, Charat , Mao, Shennen A.

Mayo Clinic

Journal of Personalized Medicine | December 2, 2022 | Volume: 12 | Issue: 12 | Pages: 1992

10.3390/jpm12121992 | PMID 36556213 Get It

Background: Our study aimed to characterize kidney transplant recipients who received high kidney donor profile index (KDPI) kidneys using unsupervised machine learning approach. Methods: We used the OPTN/UNOS database from 2010 to 2019 to perform consensus cluster analysis based on recipient-, donor-, and transplant-related characteristics in 8935 kidney transplant recipients from deceased donors with KDPI ≥ 85%. We identified each cluster’s key characteristics using the standardized mean difference of >0.3. We compared the posttransplant outcomes among the assigned clusters. Results: Consensus cluster analysis identified 6 clinically distinct clusters of kidney transplant recipients from donors with high KDPI. Cluster 1 was characterized by young, black, hypertensive, non-diabetic patients who were on dialysis for more than 3 years before receiving kidney transplant from black donors; cluster 2 by elderly, white, non-diabetic patients who had preemptive kidney transplant or were on dialysis less than 3 years before receiving kidney transplant from older white donors; cluster 3 by young, non-diabetic, retransplant patients; cluster 4 by young, non-obese, non-diabetic patients who received dual kidney transplant from pediatric, black, non-hypertensive non-ECD deceased donors; cluster 5 by low number of HLA mismatch; cluster 6 by diabetes mellitus. Cluster 4 had the best patient survival, whereas cluster 3 had the worst patient survival. Cluster 2 had the best death-censored graft survival, whereas cluster 4 and cluster 3 had the worst death-censored graft survival at 1 and 5 years, respectively. Cluster 2 and cluster 4 had the best overall graft survival at 1 and 5 years, respectively, whereas cluster 3 had the worst overall graft survival. Conclusions: Unsupervised machine learning approach kidney transplant recipients from donors with high KDPI based on their pattern of clinical characteristics into 6 clinically distinct clusters.
Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
Frank, Dmitry , Gruenbaum, Benjamin F. , Semyonov, Michael, Frenkel, Amit , Boyko, Matthew , Frenkel, Amit , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

International Journal of Molecular Sciences | December 2, 2022 | Volume: 23 | Issue: 23 | Pages: 15114

10.3390/ijms232315114 | PMID 36499434 Get It

Post-stroke depression (PSD) is a biopsychosocial disorder that affects individuals who have suffered a stroke at any point. PSD has a 20 to 60 percent reported prevalence among stroke survivors. Its effects are usually adverse, can lead to disability, and may increase mortality if not managed or treated early. PSD is linked to several other medical conditions, including anxiety, hyper-locomotor activity, and poor functional recovery. Despite significant awareness of its adverse impacts, understanding the pathogenesis of PSD has proved challenging. The exact pathophysiology of PSD is unknown, yet its complexity has been definitively shown, involving mechanisms such as dysfunction of monoamine, the glutamatergic systems, the gut-brain axis, and neuroinflammation. The current effectiveness of PSD treatment is about 30–40 percent of all cases. In this review, we examined different pathophysiological mechanisms and current pharmacological and non-pharmacological approaches for the treatment of PSD.
Cochlear Implant Awareness in the United States: A National Survey of 15,138 Adults
Marinelli, John P. , Sydlowski, Sarah, Carlson, Matthew L.

Mayo Clinic

Seminars in Hearing | December 1, 2022 | Volume: 43 | Issue: 04 | Pages: 317-323

10.1055/s-0042-1758376 | PMID 36466559 Get It

AbstractHearing loss is increasingly recognized as a chronic disease that warrants treatment. Depression, social isolation, loneliness, and poorer cognitive performance have all been linked to untreated and undertreated adult-onset hearing loss. A significant subset of the patient population with hearing loss is inadequately rehabilitated by hearing aids alone and may benefit from cochlear implantation. Yet, it is estimated that less than 10% of those who qualify have received implants to date. A national survey was conducted online in November and December 2021. Subjects were identified using Dynata panelists and river sampling. Enrollment occurred on a rolling basis. Upfront sample management techniques were used to control the distribution, balancing the respondent cohort to the 2018 U.S. Census on age, household income, sex, marital status, household size, race/ethnicity, and education. Among 15,138 adult respondents with a mean (SD) age of 51 (17) years (54% female), only 10% reported being very familiar with cochlear implants, and 31% of those with hearing difficulty reported that they have “never heard” of a cochlear implant. Females were statistically significantly more likely to report some degree of familiarity with cochlear implants than men (34 vs. 26%; p < 0.01). The greatest familiarity with cochlear implants was observed among those aged 35 to 44 years (18% reporting “very familiar”), whereas only 9% of those aged 65 to 74, 10% aged 75 to 84, and 8% ≥85 reported being very familiar (p < 0.01). Those identifying as White/Caucasian were statistically significantly more likely to report familiarity with cochlear implants than those identifying as Black/African American and Hispanic/Latino/Spanish (33 vs. 56 vs. 50% responding that they had “never heard” of cochlear implants; p < 0.01). Among adults with hearing difficulty, nearly 80% report having never talked with a medical or hearing care professional about cochlear implants. Limited cochlear implant awareness likely influences its widespread underutilization across the United States. Sex, age, and race disparities compound these issues among men, the Medicare-aged population, and those identifying as Black/African American and Hispanic/Latino/Spanish.
Nonlinear Least-Squares Estimation of Shear Wave Speeds in Viscoelastic Media
Bannon, Nicholas A., McGough, Robert J., Urban, Matthew W.

Mayo Clinic

2022 IEEE International Ultrasonics Symposium (IUS) | December 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/ius54386.2022.9957963 Get It

A time-domain fractional calculus model for shear wave parameter estimation
McGough, Robert J., Urban, Matthew W.

Mayo Clinic

2022 IEEE International Ultrasonics Symposium (IUS) | December 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1-3

10.1109/ius54386.2022.9957950 Get It

Robust Principal Component Analysis with Wavelet-Based Sparsity Promotion to Mitigate Reverberation Clutters for Ultrasound Attenuation Estimation
Lok, U‐Wai , Tang, Shanshan , Zhou, Chenyun , Watt, Kymberly D., Callstrom, Matthew R. , Trzasko, Joshua D. , Chen, Shigao , Lok, U-Wai , Gong, Ping , Huang, Chengwu , Yang, Lulu

Mayo Clinic

2022 IEEE International Ultrasonics Symposium (IUS) | December 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/ius54386.2022.9957606 Get It

Reliability of lymphoma diagnosis using combined cytologic preparations and core needle biopsy: A single-center analysis
Abbott, Marcia J. , Jiang, Liuyan , Youssef, Bahaaeldin, Siddiqi, Ahsan, Abbott, Marcia, Nassar, Aziza

Mayo Clinic

Cytojournal | December 1, 2022 | Volume: 19 | Issue: No issue available | Pages: 57

10.25259/cytojournal_22_2020 Get It

Objectives: The diagnosis of lymphoma on cytologic preparations and core needle biopsies (CNBs) is often challenging due to limited material that precludes additional ancillary testing for accurate classification. We describe our institutional experience with patients who ultimately received a diagnosis of lymphoma using cytologic preparations and CNB material along with additional ancillary testing. Material and Methods: All patients whose cytology material (fluids, cytologic smears, and cell block) and CNB resulted in a diagnosis of lymphoma, atypical lymphoid population, or suspicious for lymphoma were retrieved. Diagnoses of lymphoma followed the established nomenclatures of the World Health Organization (WHO). For all cases, the ancillary test profiles were captured and summarized. Results: Of 389 cases identified, 17 (4.4%) were diagnosed as atypical lymphoid cells and 31 (7.9%) were suspicious for lymphoma resulting in an indeterminate rate of 12.3%. The rest of the malignant cases (341; 87.7%) were classified using 2017 WHO lymphoid classification system. Six low-grade and 26 high-grade B-cell lymphomas were not further classified because of limited tissue. B-cell lymphomas were the largest category (73.0%): Primarily diffuse large B-cell lymphoma (21.4%), followed by follicular lymphoma (17.5%) and chronic lymphocytic leukemia/small lymphocytic lymphoma (10.9%). A total of 140 cases (36.0%) had flow cytometry results, but 30 specimens (21.4%) were insufficient. Cytogenetic and molecular studies were performed for 78 cases (20.0%). Conclusion: Full classification of lymphomas is possible with combined cytologic preparations and CNB material and it is an attractive first sampling modality in the diagnostic process for this disease group.
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial
Grossberg, Aaron J. , Jethwa, Krishan R. , Ellsworth, Susannah G.

Mayo Clinic

JAMA Oncology | December 1, 2022 | Volume: 9 | Issue: 2 | Pages: 275

10.1001/jamaoncol.2022.6135 | PMID 36454560 Get It

A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
Wilke, Benjamin K. , Garner, Hillary W. , Bestic, Joseph M. , Chase, Lori A. , Heckman, Michael G. , Schoch, Jennifer J. , Attia, Steven , Heckman, Michael G , Wilke, B K , Garner, Hillary W

Mayo Clinic

Clinical Cancer Research | December 1, 2022 | Volume: 29 | Issue: 3 | Pages: 541-547

10.1158/1078-0432.ccr-22-2732 | PMID 36455003 Get It

Abstract Purpose: The purpose of this pilot study was to examine the clinical efficacy and safety of serial triamcinolone injections for the treatment of desmoid tumors. Patients and Methods: Nine patients were enrolled into this prospective study and underwent three serial ultrasound-guided triamcinolone injections (120 mg) at 6-week intervals. MRI was compared at baseline and every 6 months, out to 24 months. Safety and tolerability were assessed by clinical evaluation and questionnaires, including the 12-item short form survey (SF-12), visual analog scale (VAS), and desmoid patient-reported outcome (PRO) tool. Results: At 24 months, 8 (88.9%) patients demonstrated a reduction in the volume of their tumor while 1 (11.1%) enlarged. Median tumor volume change was −26.9% (−81.1% to 34.6%; P = 0.055) All 9 tumors remained stable based on World Health Organization criteria, whereas 2 (22.2%) demonstrated partial response based on RECIST. There was a significant decrease in the tumor:muscle postcontrast mean signal intensity ratio at 6 months (P = 0.008) and 24 months (P = 0.004). There was a similar decrease in the tumor:muscle T2 mean signal intensity ratio at 24 months (P = 0.02). We found no difference in the SF-12 and VAS scores, but there were significant improvements in the desmoid PRO. Conclusions: Treatment of desmoid tumors with serial triamcinolone injections appears safe and well tolerated by patients, with a 22% partial response based on RECIST. Further research is needed to confirm our results and determine factors predictive of response.